Juno Therapeutics Inc (NASDAQ:JUNO) announced on January 5th that it selected Cindy Elkins as its new Chief Information Officer (CIO).
Following her appointment, Elkins released a statement saying that she was pleased to be joining Juno. She also recognized it as a firm that reflects her passion for accountable, vibrant and high-performing organizations with the desire to spearhead innovation and transformation at scale. She also noted that she was honored to get an opportunity to be part of a mission that aims to change the way diseases such as cancer are treated and also provides infrastructure and tools required to boost productivity from employees.
Elkins was awarded the new position based on her track record with significant roles such as the Vice President of IT at Genentech which was her most recent position before the CIO role at Juno Therapeutics. Her former role as VP involved the integration of U.S commercial technology after Genentech was bought out by Roche. Genentech was the first biotech firm to implement various major technology platforms at scale during Ms. Elkins’ leadership. Her team offered exceptional and consistent user experience to more than 44,000 people.
Before she got the job at Genentech, she was the Vice President and General Manager at an information and technology company called Ariba. She spent her tenure there creating the biggest web-based trading community in the world. Elkins is also a board member of Weight Watchers International, Inc. (NYSE:WTW)
“Cindy is a leader with a track record of increasing the impact of information technology in the biotech industry, focusing on innovation and delivering advanced technologies that support the discovery of breakthrough therapies,” stated Hans Bishop, the President, and CEO of Juno Therapeutics.
Ms. Elkins’ new position as Vice President means she will report directly to Bishop. The CEO also praised her passion, talent, and experience and also pointed out that she will play a key role in helping the company to reach its mission and to deliver better treatments to patients.
Juno Therapeutics stock closed the latest trading session on Monday at $52.62 after a 12.17 percent gain from the previous close.